Merck is currently in talks with Seagen to buy the biotech company. The Wall Street Journal reports that the deal is worth $40 billion. And what would happen when Merck buys Seagen, and how can this buyout advance cancer research and treatments. Read more about the Merck Seagen buyout here.
Merck Seagen Buyout
Merck and Seagen are still deciding on their share prices. So far, talks have yet to agree on $200 per share. Both companies want to settle and finalize their deals before Merck announces its quarterly earnings on July 28. At the time of writing, Seagen’s stock was at $176.19.
Merck’s market value is estimated at $235 billion. And their deal with Seagen can diversify their offerings to the public. Since Seagen specializes in cancer treatment, Merck will have more products to treat cancers.
Shareholder reactions to the new deal are overwhelmingly positive, and the stocks have been up since talks about the deal have been made public.
But this is not the first time that Merck and Seagen have made the news. Back in 2020, they collaborated because of cancer treatments. Seagen has a drug conjugate (ladiratuzumab vedotin) which would be used in conjunction with Merck’s Keytruda.
Merck reveals that Keytruda is its highest-selling product. It’s immunotherapy for cancer.
And this deal could help Merck offset the possibility of reduced sales because it will lose patent protection in 2028.
As promising as this deal is, there could be scrutiny from antitrust officials since there might be a litigation case from the Federal Trade Commission or Justice Department.
The Seagen buyout isn’t the only deal Merck has made recently. They’ve been busy closing another deal, but with Orion too.
Seagen
As a cancer biotech company, Seagen has therapies to ensure that patients benefit from the treatment and reduce any adverse side effects. Their treatments involve the therapy attacking tumors with toxins.
Merck partnering with Seagen isn’t a bad idea considering that Seagen made $1.4 billion in sales in 2021, most of it coming from Adcetris and Padcev (a treatment for urothelial cancers).
Merck-Orion Deal
In the middle of the Merck Seagen Buyout, Merck has recently partnered with Orion for the ODM-208 and other drugs. These drugs are related to the production of steroids. Orion found how it can combat hormone-dependent cancers and further developed this inhibitor.
Their deal includes that they should develop ODM-208 and promote it to the public together. And Orion will receive a $290 million payment from Merck.
Although they’re co-developing and marketing the new inhibitor, Orion will oversee the manufacturing side.
Co-developing the ODM-208 can help Merck with its current research and treatments for prostate cancer. President and CEO of Orion, Timo Lappalainen, says that this partnership will benefit Merck’s goals of treating cancer worldwide.
Other Ventures: Merck’s Role in the Pandemic
You may have heard about COVID-19 pills, which are a form of treatment for those diagnosed with mild to moderate COVID-19. Merck introduced an antiviral COVID-19 pill to the public. The name: Molnupiravir.
The COVID-19 pill is not a replacement for a vaccination. Instead, it stops the replication of the COVID-19 genetic code and keeps the patient out of the hospital. Not yet FDA-approved, Molnupiravir has been authorized for emergency use since December 23, 2021.
And for other stories, read more here at Owner’s Mag!
